Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for multiple myeloma (MM). In randomized studies, DARA-based regimens significantly improved response rates, depth of response including minimal ...
[2] Ola Landgren , Malin Hultcrantz , Benjamin Diamond,et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: ...
Introduction: The intravenous (IV) formulation of human CD38 mAb DARA is approved in many countries as monotherapy or in combination with standard-of-care regimens for treatment of multiple myeloma (MM). To reduce patient (pt)/provider burden and improve safety, a DARA SC co-formulation (1800...
What other option is available for treating newly diagnosed multiple myeloma in patients not intended to receive a stem cell transplant? The other option [for these patients] is dara-Rd [daratumumab (Darzalex), lenalidomide, and dexamethasone] supported by the MAIA study, looking at dara...
[3]Muchtar E,Gertz MA,Kumar SK,et al.Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.Blood,2017,129(15): 2111-2119 [4]DURER C,DURER S,LEE S,et al.Treatment of relapsed multiple myeloma:Evidence-based recommendations[J...
Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase 1b study to assess the safety and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg) in combination with a week...
There has been substantial progress in clinical outcomes for patients with multiple myeloma (MM). This encouraging trend derives in large part from the inc... J,P,Laubach,... - 《Clinical Pharmacology & Therapeutics》 被引量: 19发表: 2017年 Daratumumab, Elotuzumab, and the Development of The...
Lebow Institute for Myeloma Therapeutics; Jerome Lipper Multiple Myeloma Center Ph.D. Instructor in Medicine 主要研究方向:多发性骨髓瘤对于免疫靶向治疗的耐药机制研究和抗肿瘤药物新靶点的鉴定,围绕多发性骨髓瘤疾病进展和治疗耐药等核心问题开展研究,主要运用CRISPR-Cas9筛选系统,结合小鼠体内成瘤模型,探索在不同...
Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple MyelomaReferences1 American Cancer Society. "Multiple Myeloma Overview." Available at http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multi...
Larry D. AndersonSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX;Nitya NathwaniJudy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA;American Society of Clinical OncologyJournal of Clinical Oncology...